Intelligence Profile
Safety Profile
Evidence Limitations: The provided evidence contains limited specific safety data for mesenchymal stem cell (MSC) therapy. Most studies focus on therapeutic mechanisms rather than comprehensive safety profiles, and several clinical trials have unknown status, limiting available safety information.
Known Side Effects
Evidence is extremely thin on systematic reporting of adverse events from MSC therapy. The provided studies do not contain detailed safety profiles or comprehensive adverse event reporting. This represents a significant gap in the available evidence for assessing MSC therapy safety.
Contraindications
No specific contraindications are identified in the provided evidence. However, the absence of safety data in these studies means contraindications cannot be adequately assessed from this evidence base.
Drug Interactions
No drug interactions are reported in the provided studies. One study mentions MSC therapy combined with glutathione for methotrexate-induced mucositis, but does not report interaction data. The evidence is insufficient to draw conclusions about potential drug interactions.
Populations That Should Avoid MSC Therapy
Limited population-specific safety data is available in the provided evidence. The clinical trials suggest MSC therapy has been studied in various populations including:
- Patients with diabetes and erectile dysfunction
- Patients with lupus nephritis
- Patients with cerebellar ataxia
- Female patients with sexual function impairment
However, no specific populations are identified as needing to avoid MSC therapy based on the provided evidence.
Special Considerations
One concerning finding from the provided evidence suggests that MSC therapy may potentially drive therapeutic resistance in certain cancer patients. Specifically, one study indicates that mesenchymal stem cells can induce metabolic changes in EGFR-wild-type tumor cells that may promote resistance in EGFR-mutant non-small cell lung cancer. This warrants careful consideration in cancer patients, though more research is needed.
Evidence Gap Warning
The safety profile for MSC therapy cannot be adequately characterized from the provided evidence. Most studies focus on therapeutic mechanisms rather than systematic safety evaluation. Patients considering MSC therapy should seek comprehensive safety information from additional sources and consult with qualified healthcare providers.
Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with a healthcare provider before considering any new therapy.